Start Over


"Protocol 17S-MC-HBEH Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD) (The PRESENCE Study)"

Study Overview

The purpose of this study is to determine how LY3154207 compares with placebo in treating memory and thinking problems in individuals with mild-to-moderate Parkinson?s disease dementia.

Study Description

The primary objective is to test the hypothesis that LY3154207 administered at 10 mg, 30 mg, and/or 75 mg daily (or 50 mg based on interim analysis) (QD) oral dosing for 12 weeks will result in significant improvement in cognition in subjects with mild-to-moderate Parkinson's Disease Dementia (PDD) compared with placebo.

Additional Information

Participants will be paid for their participation.


  • IRB Number: 1709267154
  • Research Study Identifier: TX8499
  • Principal Investigator: Jared Brosch, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176